What is the typical tesamorelin dose?
The FDA-approved tesamorelin dose for HIV-associated lipodystrophy is 2 mg administered subcutaneously once daily. Research protocols typically use the same 2 mg per day dose; some research contexts use lower or higher doses for specific dose-response or pharmacokinetic studies.
What the research literature says
The 2 mg per day dose was established as the clinical-development standard through the Falutz pivotal NEJM trial in HIV-associated lipodystrophy (PMID 18057338), the long-term safety extension (PMID 18690162), and the pooled phase 3 analysis (PMID 20554713). The dose produces sustained pituitary GHRH-receptor stimulation supporting daily GH-release pulses and downstream IGF-1 elevation across multi-month treatment periods.
The Tomlinson drug evaluation (PMID 17086939) and the Spooner pharmacotherapy review (PMID 22298602) cover the dose-justification framework. Secondary clinical analyses extended the same 2 mg per day framework into inflammatory-marker improvements (PMID 21516030), metabolic-profile improvements (PMID 22495074), and liver-enzyme improvements (PMID 28832410).
The dose is anchored to the daily-dosing schedule by the compound’s short ~25-40 minute plasma half-life — sustained pituitary stimulation requires daily dosing because longer intervals would produce only intermittent GH pulses without supporting the integrated downstream IGF-1-axis response.
Why this matters in research context
The 2 mg per day dose is the operational anchor across both clinical practice and most research-supply protocols. Deviations to lower or higher doses should be justified by specific experimental design considerations — the dose has been extensively characterised in the clinical-trial literature and the dose-response framework is well-established.
Related compounds
- Tesamorelin 10mg — the compound covered by this answer
Related research questions
- What is the half-life of tesamorelin?
- How much bacteriostatic water with tesamorelin?
- Does tesamorelin raise IGF-1?
References
- Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006;7(10):952-961. [PMID 17086939]
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304. [PMID 20554713]
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012;46(2):240-247. [PMID 22298602]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tesamorelin is sold strictly as a research-grade reagent for laboratory and bench research applications.